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Abstract. This paper deals with the study of correction of L-NAME-induced endothelial 
dysfunction by means of 3-(2,2,2-trimethylhydrazinium) propionate derivatives. We have shown 
that 3-(2,2,2-trimethylhydrazinium) propionate and its derivatives reduced the expression of NO-
deficient endothelial dysfunction induced by intraperitoneal administration of N-nitro L-arginine 
methyl ester (L-NAME), improved the parameters of endothelium-dependent vasodilation in 
response to administration of acetylcholine, and reduced the coefficient of endothelial 
dysfunction. It was revealed that the 5-hydroxinicotinate 3-(2,2,2-trimethylhydrazinium) 
potassium propionate has the most pronounced endothelioprotective effect. 
Keywords: endothelial dysfunction; 3-(2,2,2-trimethylhydrazinium) propionate; L-NAME. 
 
Introduction.Currently, the dysfunction of the 
vascular endothelium is considered one of the leading 
factors in the pathogenesis of heart and blood vessel 
diseases [1, 2, 3, 4, 5, 6, 7]. The unique position of 
endothelial cells at the interface between circulating 
blood and tissues makes them the most vulnerable to 
a variety of pathogenic factors present in the system 
and the tissue blood flow. These cells are the first to 
meet with reactive free radicals, oxidized low density 
lipoproteins, hypercholesterolemia, high hydrostatic 
pressure inside the blood vessels they line (in arterial 
hypertension), and hyperglycemia (in diabetes 
mellitus). All of these factors lead to damage of the 
vascular endothelium, and further to endothelial 
dysfunction (ED) [8, 9, 10, 11, 12, 13]. Among all 
the factors synthesized by the endothelium, the main 
role is played by endothelial relaxation or nitrogen 
oxide (NO). This compound regulates the activity 
and the sequence of “launch" of all other 
endothelium-produced bioactive substances.  
NO, synthesized by endothelial NO-synthase 
(eNOS) is one of the key regulators of vascular tone. 
Arterial hypertension, a powerful risk factor for 
cardiovascular diseases, is characterized by the 
formation of excessive reactive species of oxygen in 
the body that interact with NO and thereby reduce its 
bioavailability, and cause oxidative stress when 
oxidizing NO to peroxynitrite [14, 15]. 
Increased production of ROS (reactive oxygen 
species) in vascular disorders is accompanied by 
severe dysfunction of the vascular endothelium. 
Production of any of ROSs can cause the formation 
of several others. All of them are accumulated in the 
cell membrane, and may have adverse effects on cell 
functions [15, 16, 17, 18].  
Experimental modeling of arterial hypertension 
in animals showed that an increase in ROS leads to 
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endothelial dysfunction, as evidenced by the 
improvement of endothelium-dependent relaxation 
upon application of antioxidants [4]. 
Chronic renal failure in animals leads to 
increased production of ROS and decreased NO 
bioavailability and therefore to the development of 
endothelial dysfunction, correctable with antioxidant 
pre-treatment [16, 17]. 
In this context, the objective of our study was to 
investigate endotelio- and cardioprotective activity of  
3-(2,2,2-trimethylhydrazinium) propionate (mildronat) 
and its derivatives (nicotinate, 5-bromonicotinate,  
5-hydroxinicotinate, glycinate) 3-(2, 2,2-
trimethylhydrazinium) propionate) in the model of L-
NAME induced nitrogen oxide deficiency. 
Materials and research methods. We studied 4 
chemical derivatives of 3-(2,2,2-
trimethylhydrazinium) propionate (derivatives of  
3-(2,2,2-trimethylhydrazinium) potassium 
propionate, which are synthesized by the All-Russian 
Scientific Center of biologically active substances 
(ARSC BAS) and reference drug Mildronate
®
 (by 
“Grindeks” JSC). 
The study of endothelioprotective activity was 
conducted on albino male Wistar rats weighing 
250±50 g. Endothelial dysfunction was simulated by 
intraperitoneal administration of nonselective NO-
synthase blocker - N-nitro-L-arginine methyl ester 
(L-NAME) at a dose of 25 mg/kg/day for 7 days.  
On day 8 of the experiment, a catheter was 
inserted under anesthetisia (chloral hydrate  
300 mg/kg) into the left carotid artery to record blood 
pressure (BP). Bolus administration of 
pharmacological agents was into the femoral vein. 
Hemodynamic parameters: systolic blood pressure 
(SBP), diastolic blood pressure (DBP) and heart rate 
(HR) were measured continuously with the use of a 
sensor and the computer program “Biopac Systems, 
Inc.", USA. In addition to blood pressure 
measurements, a series of functional tests was 
performed with subsequent evaluation of changes in 
hemodynamic parameters (SBP, DBP, HR) in 
response to an intravenous administration of solution 
of acetylcholine (ACh) at a dose of 40 mg/kg at the 
rate of 0.1 ml per 100 g body weight of animal 
(EDVD) , as well as changes in hemodynamic 
parameters in response to the intravenous 
administration of sodium nitroprusside (NP) at a dose 
of 30 mg/kg at the rate of 0.1 ml per 100 g body 
weight of animal (EIVD) [17, 19, 20, 21] . 
The degree of endothelial dysfunction in 
experimental animal, as well as the degree of its 
correction with the studied medications was assessed 
by the estimated coefficient of endothelial 
dysfunction (EDC), which represents the ratio of the 
area of a triangle above the BP recovery curve in 
response to the NP administration (EIVD) to the area 
of a triangle above the BP recovery curve in response 
to the AH administration (EDVD) [1, 3, 4, 7]. 
Mildronate
®
 and the derivatives were administered 
intraperitoneally once daily for 7 days. Experimental 
animals were divided into groups (n=10): I - intact; II 
- L-NAME-administered; III - with the 
administration of Mildronate ("Grindeks") at a dose 
of 90 mg/kg on the background of L-NAME, IV - 
with the administration of nicotinate 3- (2,2,2-
trimethylhydrazinium) potassium propionate at a 
dose of 189 mg/kg on the background of L-NAME, 
V - with the administration of bromonicotinate 5-3- 
(2,2,2-trimethylhydrazinium) potassium propionate at 
a dose of 189 mg/kg on the background of L-NAME, 
VI - with the administration of glycinate 3-( 2,2,2-
trimethylhydrazinium) potassium propionate at a 
dose of 199 mg/kg on the background of L-NAME, 
and VII – with the administration of  
5-hydroxinicotinate 3-(2,2,2-trimethylhydrazinium) 
potassium propionate at a dose of 159 mg/kg on the 
background of L-NAME. Doses of the investigated 
derivatives were calculated from molar weight by 
reference drug Mildronate
®
, in equivalent to 
laboratory animals. 
To evaluate the functionality of the myocardium 
of animals under controlled respiration, the left 
ventricular cavity was probed with a needle through 
the heart top and the parameters of 
cardiohemodynamics of the left ventricular pressure 
(LVP) were recorded with the sensor RX104A 
"Biopac Systems, Inc." and the computer program 
"Biopac Systems, Inc.", USA. Myocardial 
functionality was assessed by conducting a series of 
stress tests in animals: test for adrenoreactivity (a 
one-time intravenous administration of epinephrine 
hydrochloride solution 1
 .
10
-5
 mol/L at the rate of 0.1 
ml per 100 g), and the resistance load (ascending 
aorta compression for 30 seconds). 
Results and discussion. It was found that the 
studied drugs did not prevent development of severe 
hypertension, and systolic and diastolic blood 
pressure values were significantly higher than the 
corresponding values in intact animals in all series of 
experiments, except for 5-hydroxinicotinate 3- (2,2,2-
trimethylhydrazinium) potassium propionate and  
5-bromonicotinate 3-(2,2,2-trimethylhydrazinium) 
potassium propionate, where SBP and DBP were 
183.1±3.5 and 125.1±4.3 and 180.3±6.3 and 
132.5±4.8, respectively. 
The effect of Mildronate
®
 and test substances on 
the initial blood pressure in anesthetized rats with 
simulated L-NAME-induced pathology are presented 
in Fig. 1. 
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I – Intact; II – L-NAME; III – Mildronate® at a dose of 90 mg/kg; IV – nicotinate at a dose of 189.2 mg/kg;  
V – 5-bromonicotinate at a dose of 237 mg/kg; VI – 5-hydroxinicotinate at a dose of 199.1 mg/kg; VII – glycinate at a dose of 
159.6 mg/kg (3-(2,2,2-trimethylhydrazinium) potassium propionate) 
Figure 1. The influence of the derivatives of 3-(2,2,2-trimethylhydrazinium) potassium propionate on the systolic and 
diastolic blood pressure in modeling L-NAME (intraperitoneal administration of L-NAME at a dose of 25 mg/kg for 7 days)-
induced deficiency of nitrogen oxide. 
Note: *- at p = 0.05 as compared to L-NAME; **- at p = 0.05 as compared to intact animals. 
 
Fig. 2 shows the results of functional tests for 
endothelium-dependent (acetylcholine, 40 µg/kg i.v.) 
and endothelium-independent (nitroprusside 30 mg/kg 
i.v.) vascular relaxation in animals with L-NAME-
induced pathology during the treatment with the studied 
medications, followed by EDC calculation. 
It is noteworthy that Mildronate
®
 and all its 
derivatives led to a significantly pronounced decrease 
of EDC. We found that Mildronate® reduces EDC up 
to 2.8±0.1, whereas EDC in the group of animals 
treated with L-NAME was 5.3±0.6. 
The studied derivatives significantly reduced 
EDC as compared to the control group up to 1.6±0.3, 
1.8±0.6, 1.9±0.5, 2.4± 0.5, respectively. 
Test for adrenoreactivity revealed a significant 
decrease in the maximum rise of left ventricular 
pressure in response to intravenous administration of 
adrenaline in rats treated with Mildronate
®
 up to 
230.8±6.7 mm Hg, as compared to a group of 
untreated animals - 254.2±7.8 mm Hg (p<0.05), 
which indicates the prevention of increase in 
adrenoreactivity during treatment. Derivatives of 
nicotinate and 5-hydroxinicotinate (3-(2,2,2-
trimethylhydrazinium) potassium propionate) 
maximally prevented the increase in adrenoreactivity 
up to 192.6±5.4 and 163.9 ± 7.1 mm HG caused by 
L-NAME-induced pathology. Adrenoreactivity of  
5-bromonicotinate and glycinate (3- (2,2,2-
trimethylhydrazinium) potassium propionate) was 
223.5±8.4 and 213.4±6.9 mm Hg, respectively. 
Test for resistance load showed that Mildronate
®
 
and all its derivatives prevented the drop of 
contractility in the period from 5 to 25 second of 
aortic compression on the background of endothelial 
dysfunction modeling. So, myocardial reserve on the 
25th second of the test was 83.6±2.1% of the value at 
the 5th seconds in intact animals.In the control group 
(L-NAME-induced nitrogen oxide deficiency) – 
66.0±2.3% administration of Mildronate® to rats 
contributed to the maintenance of myocardial reserve 
at a level of 78.5±4.1. Pretreatment with the 
derivatives (nicotinate, 5-bromonicotinate,  
5-hydroxinicotinate, glycinate) 3-(2,2,2-
trimethylhydrazinium) potassium propionate) during 
the resistance load test approximated the values to the 
level of intact animals: 72.5±2.1%, 82.3±3.9%, 
78.1±6.1% and 70.9±5.8%, respectively. 
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I – Intact; II – L-NAME; III – Mildronate® at a dose of 90 mg/kg; IV – nicotinate at a dose of 189.2 mg/kg;  
V – 5-bromonicotinate at a dose of 237 mg/kg; VI – 5-hydroxinicotinate at a dose of 199.1 mg/kg; VII – glycinate at a dose of 
159.6 mg/kg (3-(2,2,2-trimethylhydrazinium) potassium propionate) 
Figure 2. The influence of the derivatives of 3-(2,2,2-trimethylhydrazinium) potassium propionate on the endothelial 
dysfunction coefficient in modeling L-NAME (intraperitoneal administration of L-NAME at a dose of 25 mg/kg for 7 days)-
induced deficiency of nitrogen oxide. 
Note: *- at p = 0.05 as compared to L-NAME; **- at p = 0.05 as compared to intact animals. 
 
Currently, it is considered promising to correct 
the conditions involving endothelial dysfunction with 
the drugs having antioxidant activity, as the main 
mechanism underlying endothelial dysfunction is a 
reduction of production and bioavailability of NO 
under simultaneous increase in the level of 
superoxide anion due to increased oxidative activity 
of NADP [17, 20, 21].  
3-(2,2,2-trimethylhydrazinium propionate), 
which itself does not have antioxidant properties, 
increases the body's concentration of gamma-
butyrobetaine (GBB), due to being oxidized to 
carnitine slower than usual under the influence of 3-
(2,2,2-trimethylhydrazinium propionate). The GBB, 
in turn, can induce the formation of NO, which is one 
of the most efficient absorbents of free radicals in the 
body. 3-(2,2,2-trimethylhydrazinium propionate), by 
increasing the number of GBBs, is able to protect 
cells from free radical effects, but this is realized 
indirectly through the induction of NO biosynthesis. 
Therefore, 3-(2,2,2-trimethylhydrazinium propionate) 
contributes to the development of physiologically 
controlled amount of NO, allowing the body to 
ensure the necessary level of protection from 
radicals. There are lot of researhes devoted to the 
application of 3-(2,2,2-trimethylhydrazinium) 
propionate in cardiovascular diseases. It is generally 
known that 3-(2,2,2-trimethylhydrazinium) 
propionate leads to restricted flow of fatty acids 
through the mitochondrial membrane and protects 
cell from death under oxygen deficiency. A question 
of a new mechanism of action of 3-(2,2,2-
trimethylhydrazinium) propionate by the type of 
ischemic preconditioning is under study. Analyzing 
the implementation stage of the protective effects by 
preconditioning type, many researchers pay attention 
to the significant role of ATP-dependent potassium 
channels (KATF channels) through the activation of 
NO [22, 23].  
By introduced into the molecule of 3-(2,2,2-
trimethylhydrazinium propionate) the nicotinic acid 
and its derivatives, namely 5-bromonicotinate, 5-
hydroxinicotinate, and glycinate having various 
degrees of antioxidant activity, it is expected to 
identify new properties and strengthening of effects 
in the treatment of cardio-vascular diseases. 
For example, such substances as  
5-hydroxinicotinate, 5-bromonicotinate (3-(2,2,2-
trimetilgidroziny) potassium propionate), have 
significantly, unlike other substances, affected the 
hemodynamic parameters in the model of L-NAME-
induced NO deficiency and lowered systolic and 
diastolic blood pressure up to the following values: 
183.1±3.5 and 125.1±4.3 mm Hg, and 180.3±6.3 and 
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132.5±4.8 mm Hg, respectively. The maximum 
decrease in EDC is typical of the three presented 
modifications: nicotinate, 5-bromonicotinate, and 5-
hydroxinicotinate (3-(2,2,2-trimetilgidroziny) potassium 
propionate), 1.6±0.3, 1.8±0.6, and 1.9±0.5, respectively. 
The conducted experimental studies allow 
suggesting that both Mildronate
® 
and all its derivatives 
have a pronounced endothelium- and cardioprotective 
effect on the model of L-NAME-induced NO 
deficiency, which was reflected in the predominance of 
endothelium-dependent relaxation of blood vessels and 
reduced coefficient of endothelial dysfunction, the 
prevention of increase in adrenoreactivity and the drop 
of LV contractility and pressure. 
Given the important role of ED in the 
development of oxidative stress, it can be assumed 
that the substances with antioxidant effect may affect 
the various elements of ED development such as NO 
synthesis and bioavailability system, 
hemorheological parameters of blood, lipid and 
carbohydrate metabolism, inflammation, and 
proliferation. Therefore, the search for highly active 
endotelioprotectors among the compounds with 
antioxidant activity is fully justified.  
Subject to the above, the therapeutic effect of the 
use of investigated derivatives of 3-(2,2,2-
trimethylhydrazinium) propionate, which is higher as 
compared to the basic molecule, according to the 
obtained data, could be due to either addiction or 
potentiation of properties being a part of the active 
components of the molecule.   
Furthermore, pharmacological composition that 
throughout the entire study showed endothelio- and 
cardioprotective effects contains a hydroxyl group, 
which enhances the antioxidant properties of a 
molecule, which in combination with the activation 
of the ATP-dependent potassium channels and stress 
exposure leads to realization of the effects of 
ischemic preconditioning, normalization of the 
energy balance in the cell, and the maximum anti-
ischemic, and endotelio- and cardioprotective effects 
in the range of investigated 3-(2,2,2-
trimethylhydrazinium) propionate. 
Conclusions. 
1. (3-(2,2,2-trimethylhydrazinium) propionate 
(Mildronate
®
) and its derivatives (nicotinate,  
5-bromonicotinate, 5-hydroxinicotinate, glycinate)  
3-(2,2,2-trimethylhydrazinium) propionate 
potassium) have expressed endotelio- and 
cardioprotective effect on the model of L-NAME-
induced nitrogen oxide deficiency, which indicates 
their contribution to NO-ergic system. 
2. All of the derivatives in the range of  
3-(2,2,2-trimethylhydrazinium) propionate have the 
most pronounced endothelio- and cardioprotective 
effect on the model of L-NAME induced nitrogen 
oxide deficiency as compared to the reference drug 
(Mildronate
®
), which confirms the feasibility of their 
further enhanced study. 
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